Chaitanya Stem Cell Center

Regenerative Therapy has proven to be effective for organs and tissues restoration, and for fight against the incurable and obstinate diseases. We treat patients with various diseases, such as diabetes mellitus, multiple sclerosis, Parkinsons disease, Duchenne muscular dystrophy, and many others, including rare genetic and hereditary diseases. Among our patients there are also people willing to undergo anti-aging treatment. Stem cell treatment allows for achieving effects that are far beyond the capacity of any other modern method our stem cell treatments helped to prolong life and improve life quality to thousands of patients including those suffering from the incurable diseases who lost any hope for recovery.

Chaitanya Stem Cell Centre is dedicated to providing Neurological, Kidney, Liver, Endocrinal disease and many untreatable disease patients with information about Regenerative Therapy at Pune India. We have achieved high success rate up to 80% Patient success rate as per our standardized Protocol.

We have successfully improved more than 600 patients from 14 countries, till todate. Our clinic offers advanced patented methods of stem cell treatment for different diseases and conditions. The fetal stem cells we use are nonspecialized cells able to differentiate (turn) into any other cell types forming different tissues and organs. Fetal stem cells have huge potential for differentiation and proliferation and are not rejected by the recipients body.

Want to find out more about Regenerative Therapy with no obligation? Visit our center and get interacted with many of our satisfied and cured patient. Our Regenerative Therapy is based on many years of research and clinical experience conducted by researchers and clinicians in the India.

Covering over 25 treatable conditions, including Neurological, Kidney, Liver, Endocrinal disease and many untreatable disease provides both Allogenic and Autologous stem cell treatment programs, has a growing body of patient testimonials, updated articles, frequently asked questions and more.

Link:
Chaitanya Stem Cell Center

Stem Cell and Regenerative Medicine – University of Rochester …

The University of Rochester Stem Cell and Regenerative Medicine Institute was founded in 2008 in recognition of the tremendous promise that the discipline of stem cell biology offers for our understanding of development, disease and discovery of new treatments for a wide range of afflictions. Much as the discoveries of antibiotics and vaccination revolutionized our abilities to treat disease and reduce suffering, the discoveries of stem cell biology are poised to provide similar benefits

The University of Rochester is home to a rich and diverse stem cell faculty, with more than 40 faculty from 15 different departments, and more than 35 research track faculty and senior research fellows. These laboratories are collectively home to over 200 staff, including multiple Ph.D. students, postdoctoral fellows, M.D./Ph.D. students and technical fellows. Currently committed research awards, center grants, training grants and industry sponsored programs generated by this faculty represent over $60 million in direct cost commitments. Several of the programs at the University of Rochester Medical Center (URMC) are among the top programs both nationally and internationally. For example, there is particular strength in the field of neuromedicine, particularly in the context of the stem and progenitor cells giving rise to the glial cells of the central nervous system, with the faculty at URMC including several of the international leaders in such research. The Center for Musculoskeletal Research is rated as the No. 1 orthopaedics group in the United States in NIH funding. In the newly evolving field of cancer stem cell biology, a team of leading individuals also has been assembled, with drugs discovered through this effort already entering clinical trials. This intellectual environment is associated with large numbers of patent applications and with multiple opportunities for translating discoveries into therapies.

The research interests of faculty associated with University of Rochesters Stem Cell and Regenerative Medicine Institute range from model organisms to treatment of neurological disease, from investigations on the origins of red blood cells to the developing approaches to the treatment of fractures and osteroporosis, from studies on how to protect the body from the toxic effects of current cancer treatments to the development of new treatments that target cancer cells while sparing the normal cells of the body.

The following are recent news and events from our Institute:

Read the original:
Stem Cell and Regenerative Medicine - University of Rochester ...

BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.7 Million Grant From Israel’s Office of the Chief Scientist

We thank the Israel Office of the Chief Scientist for their commitment to innovation and their continuing support of our development of a cell therapy based treatment for a major disease of aging, said Charles Irving, PhD, Chief Executive Officer of Cell Cure.

I join with Dr. Irving in thanking the OCS for their generous support in acclerating pluripotent stem cell research into clinical applications, said Benjamin Reubinoff, MD, PhD, Chief Scientific Officer of Cell Cure and Chairman of Obstetrics and Gynecology and Director of the Hadassah Human Embryonic Stem Cell Research Center at Hadassah University Medical Center, Jerusalem, Israel. The dry form of age-related macular degeneration afflicts over seven million people in the United States alone. We anticipate that OpRegen will make a real difference in the quality of life of the aging baby-boomer generation afflicted with this condition in many industrialized countries.

The OCS has previously provided grants to Cell Cure. Cell Cure will pay a royalty to the OCS on revenues from OpRegen until total royalties paid equal 100% of the amount of the grant plus interest at a LIBOR rate. Historically, Cell Cure Neurosciences or BioTimes other subsidiaries have raised capital, received grants, or generated revenues independently ofBioTimeto help fund their operations. We expect Cell Cure Neurosciences to continue to pursue such financing strategies in the future.

About the Office of the Chief Scientist

The Office of the Chief Scientist in the Ministry of Industry, Trade and Labor is charged with the execution of government policy for the support of industrial R&D.The goal of the OCS is to assist in the development of technology in Israel as a means of fostering economic growth, encouraging technological innovation and entrepreneurship, leveraging Israels scientific potential, enhancing the knowledge base of industry in Israel, stimulating high value-added R&D, and encouraging R&D collaboration both nationally and internationally. A variety of ongoing support programs developed and offered by the OCS play a major role in enabling Israel to be a key center for high-tech entrepreneurship.

About Cell Cure Neurosciences Ltd.

Cell Cure Neurosciences Ltd. was established in 2005 as a subsidiary of ES Cell International Pte. Ltd. (ESI), now a subsidiary of BioTime, Inc. (NYSE MKT: BTX). Cell Cure is located in Jerusalem, Israel on the campus of Hadassah University Hospital. Cell Cure's mission is to become a leading supplier of human cell-based therapies for the treatment of retinal and neural degenerative diseases. Its technology platform is based on the manufacture of diverse cell products sourced from clinical-grade (GMP) human embryonic stem cells. Its current focus is the development of retinal pigment epithelial (RPE) cells for the treatment of age-related macular degeneration. Cell Cure's major shareholders include BioTime, Inc., Hadasit BioHoldings Ltd. (Tel Aviv Stock Exchange: HDST), and Teva Pharmaceuticals Industries Ltd. (NYSE: TEVA). Additional information about Cell Cure can be found on the web at http://www.cellcureneurosciences.com. A video of a presentation by Cell Cures CEO Dr. Charles Irving is available on BioTimes web site.

About BioTime, Inc.

BioTime is a biotechnology company engaged in research and product development in the field of regenerative medicine. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. BioTimes focus is on pluripotent stem cell technology based on human embryonic stem (hES) cells and induced pluripotent stem (iPS) cells. hES and iPS cells provide a means of manufacturing every cell type in the human body and therefore show considerable promise for the development of a number of new therapeutic products. BioTimes therapeutic and research products include a wide array of proprietary PureStem progenitors, HyStem hydrogels, culture media, and differentiation kits. BioTime is developing Renevia (a HyStem product) as a biocompatible, implantable hyaluronan and collagen-based matrix for cell delivery in human clinical applications. In addition, BioTime has developed Hextend, a blood plasma volume expander for use in surgery, emergency trauma treatment and other applications. Hextend is manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ CheilJedang Corporation under exclusive licensing agreements.

BioTime is also developing stem cell and other products for research, therapeutic, and diagnostic use through its subsidiaries:

View original post here:
BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.7 Million Grant From Israel’s Office of the Chief Scientist

FRONTLINE CANCER: Working to eliminate the cancer stem cells that sustain disease

By Scott M. Lippman

Chemotherapies seek out cancer cells by targeting a fundamental characteristic of cancer cells: their rapid and frequent replication. But in doing so, these drugs can destroy healthy cells that also grow quickly. The result: adverse effects like hair loss and nausea.Worse, the benefits of chemotherapy are frequently short-lived. Seemingly beaten by chemotherapy, a cancer can suddenly return, spreading from its original site to other parts of the body with often catastrophic consequences. Ninety percent of cancer-related deaths are due to metastasis, and almost every cancer can be metastatic.

Why do cancers recur when therapeutic evidence suggests theyve been wiped out? The answer lies in a type of cancer cell with the powerful characteristic of normal stem cells the ability to self-renew or regenerate.

Sott M. Lippman, M.D.

Unlike normal stem cells, however, this ability in cancer stem cells does not turn off.

Cancer stem cells are a relatively new phenomenon to cancer science. Conclusive evidence of their existence was found only in 1994, though in the years since, extraordinary efforts have been made to better understand them in order to destroy them.

Its a daunting task. Cancer stem cells persist in small communities, often tucked away in the deep recesses of bone. They do not divide with dangerous abandon, which would make them easier targets of chemotherapy. In fact, they often lie dormant, essentially invisible until they begin again the process of self-renewal, differentiation and cancer relapse.

Toughest of all, they are very hard to kill, quickly developing resistance to existing drug therapies.

Nonetheless, progress is being made, some of it driven by researchers at UC San Diego Moores Cancer Center. Among them is Catriona Jamieson, M.D., Ph.D., an associate professor of medicine in the UC San Diego School of Medicine and director of Stem Cell Research at Moores Cancer Center.

Jamieson has devoted much of her career to deciphering the secrets of cancer stem cells and, more importantly, working to develop effective treatments to rid the body of them. She specializes in myeloproliferative neoplasms (MPNs) and leukemia.

See the rest here:
FRONTLINE CANCER: Working to eliminate the cancer stem cells that sustain disease

stem cell research – University of Rochester Medical Center …

The University of Rochester Stem Cell and Regenerative Medicine Institute was founded in 2008 in recognition of the tremendous promise that the discipline of stem cell biology offers for our understanding of development, disease and discovery of new treatments for a wide range of afflictions. Much as the discoveries of antibiotics and vaccination revolutionized our abilities to treat disease and reduce suffering, the discoveries of stem cell biology are poised to provide similar benefits

The University of Rochester is home to a rich and diverse stem cell faculty, with more than 40 faculty from 15 different departments, and more than 35 research track faculty and senior research fellows. These laboratories are collectively home to over 200 staff, including multiple Ph.D. students, postdoctoral fellows, M.D./Ph.D. students and technical fellows. Currently committed research awards, center grants, training grants and industry sponsored programs generated by this faculty represent over $60 million in direct cost commitments. Several of the programs at the University of Rochester Medical Center (URMC) are among the top programs both nationally and internationally. For example, there is particular strength in the field of neuromedicine, particularly in the context of the stem and progenitor cells giving rise to the glial cells of the central nervous system, with the faculty at URMC including several of the international leaders in such research. The Center for Musculoskeletal Research is rated as the No. 1 orthopaedics group in the United States in NIH funding. In the newly evolving field of cancer stem cell biology, a team of leading individuals also has been assembled, with drugs discovered through this effort already entering clinical trials. This intellectual environment is associated with large numbers of patent applications and with multiple opportunities for translating discoveries into therapies.

The research interests of faculty associated with University of Rochesters Stem Cell and Regenerative Medicine Institute range from model organisms to treatment of neurological disease, from investigations on the origins of red blood cells to the developing approaches to the treatment of fractures and osteroporosis, from studies on how to protect the body from the toxic effects of current cancer treatments to the development of new treatments that target cancer cells while sparing the normal cells of the body.

The following are recent news and events from our Institute:

Read more from the original source:
stem cell research - University of Rochester Medical Center ...

Stem cell technology

Stem cell technology is a rapidly developing field that combines the efforts of cell biologists, geneticists, and clinicians and offers hope of effective treatment for a variety of malignant and non-malignant diseases. Stem cells are defined as totipotent progenitor cells capable of self renewal and multilineage differentiation.1 Stem cells survive well and show stable division in culture, making them ideal targets for in vitro manipulation. Although early research has focused on haematopoietic stem cells, stem cells have also been recognised in other sites. Research into solid tissue stem cells has not made the same progress as that on haematopoietic stem cells. This is due to the difficulty of reproducing the necessary and precise three dimensional arrangements and tight cell-cell and cell-extracellular matrix interactions that exist in solid organs. However, the ability of tissue stem cells to integrate into the tissue cytoarchitecture under the control of the host microenvironment and developmental cues, makes them ideal for cell replacement therapy. In this overview, we briefly discuss the current research and the clinical status of treatments based on haematopoietic and tissue stem cells.

Stem cells are progenitor cells that are capable of self renewal and differentiation into many different cell lineages

Stem cells have potential for treatment of many malignant and non-malignant diseases

Peripheral blood stem cells are used routinely in autologous and allogeneic bone marrow transplantation

Gene transfer into haematopoetic stem cells may allow treatment of genetic or acquired diseases

Embryonic stem cells may eventually be grown in vitro to produce complex organs

Neuronal stem cells are being used for neurone replacement in neurovegetative disorders such as Parkinson's and Huntingdon's diseases

Haematopoietic stem cells are a somatic cell population with highly specific homing properties and are capable of self renewal and differentiation into multiple cell lineages.2 Human haematopoietic progenitor cells, like stromal cell precursors in bone marrow, express the CD34 antigen, a transmembrane cell surface glycoprotein identified by the My10 monoclonal antibody.3 However, pluripotent stem cells constitute only a small fraction of the whole CD34+ population, which is by itself rather heterogeneous regarding phenotype and function. The best way to define haematopoietic stem cells is from their functional biology. They are known to restore multilineage, long term haematopoietic cell differentiation, and maturation in lethally cytoablated hosts.4 Haematopoietic stem cells can be obtained from bone marrow, peripheral blood,5 umbilical cord blood,6 and fetal liver.7

The use of peripheral blood stem cells in both autologous and allogeneic transplantation has become routine as they can be collected on an outpatient basis and also promote a consistent acceleration in haematopoietic reconstitution after engraftment.8 Umbilical cord blood stem cells have been used progressively in paediatric patients, from both related and unrelated HLA-matched donors. In recipients with severe T cell immunodeficiency disorders, fast engraftment is required together with a low risk of graft versus host disease and a low viral transmission rate.9 Since umbilical cord blood stem cells can be expanded in vitro or frozen for storage in cell banks10 they have been used in clinical trials for both autologous and allogeneic haematopoietic stem cell transplantation.11

The bone marrow is a mesenchyme derived tissue consisting of a complex haematopoietic cellular component supported by a microenvironment composed of stromal cells embedded in a complex extracellular matrix.12 This extracellular matrix has an important role in the facilitation of cell-to-cell interaction, in addition to a more complex role in the binding and presentation of cytokines to the haematopoietic progenitor cells.13 The cytokine milieu and extracellular matrix interaction provides the road map for maturation and differentiation of stem cells,14 which should be instrumental for their in vitro manipulation before therapeutic use. For example, haematopoietic stem cells can be manipulated in vitro to generate dendritic cells, the most potent antigen presenting cells.

Read more:
Stem cell technology

HEXIM1 regulatory protein induces human pluripotent stem cells to adopt more specialized cell fate

5 hours ago Human pluripotent stem cells, such as human embryonic stem cells (above), can differentiate into specific cell types under appropriate conditions; the HEXIM1 protein helps with this differentiation. Credit: DAJ/amana images/Thinkstock

A lot of optimism and promise surrounds the use of human pluripotent stem cells (hPSCs)for applications in regenerative medicine and drug discovery. However, technical challenges still hamper the culturing and differentiation of these cells, which include the cell types known as human embryonic stem cells (hESCs) and their reprogrammed equivalents, induced pluripotent stem cells (iPSCs).

A team of A*STAR scientists has now discovered a regulatory protein that helps to coax human pluripotent stem cells to form more specialized types of cells. "Our finding could help to develop a new protocol to induce differentiation of human pluripotent stem cells," says Sheng-Hao Chao from the A*STAR Bioprocessing Technology Institute (BTI) in Singapore, who led the study.

Chao and his co-workers at the BTI's Expression Engineering Group have been studying a protein called hexamethylene bisacetamide-inducible protein 1 (HEXIM1) for many years. HEXIM1 is known to inhibit a protein complex called positive transcription elongation factor b (P-TEFb), which is involved in gene expression. Chao's team previously linked HEXIM1 with a specific pathway involved in cancer development. This led the researchers to suspect an additional role for HEXIM1 in regulating stem cells.

Chao's group teamed up with Andre Choo and his colleagues in the Stem Cell Group at the BTI to further explore this possibility. They first treated hESCs with a differentiation-inducing compound called LY294002 and saw a marked increase in HEXIM1 levels compared to untreated cells.

Further tests showed that HEXIM1 played a role in driving cellular differentiation. For example, the hESCs differentiated when the researchers incubated the cells with hexamethylene bisacetamide (HMBA), a HEXIM1 inducing reagent, or when they generated and cultured a cell line with elevated expression of HEXIM1. The researchers rule out P-TEFb inhibition as an explanation for the effect, however, because in another experiment, hESCs treated with flavopiridola drug that blocks P-TEFb activityremained in a pluripotent state.

"We discovered a novel function of HEXIM1 in regulating the early-stage differentiation of human pluripotent stem cells through a P-TEFb-independent pathway," says Chao. More work is still needed to investigate in detail the molecular mechanism by which HEXIM1 drives hPSC differentiation.

Eventually, HEXIM1 could become a useful tool in generating new tissues for cell-replacement therapies. "In combination with other transcription factors or chemicals, it is possible that HEXIM1 and its inducing reagent HMBA could be utilized to direct the differentiation of human pluripotent stem cellsinto specific cell types," Chao says.

Explore further: Scientists engineer human stem cells

More information: Ding, V., Lew, Q. J., Chu, K. L., Natarajan, S., Rajasegaran, V. et al. "HEXIM1 induces differentiation of human pluripotent stem cells." PLoS ONE 8, e72823 (2013). dx.doi.org/10.1371/journal.pone.0072823

Read the original:
HEXIM1 regulatory protein induces human pluripotent stem cells to adopt more specialized cell fate

UC Davis Institute for Regenerative Cures – UC Davis Health System

For patients and families suffering from chronic disease or injury, the promise of stem cell therapies offers great hope. UC Davis is a leader in advancing that promising goal. It has brought together physicians, research scientists, biomedical engineers and a range of other experts and collaborative partners to establish the UC Davis Institute for Regenerative Cures, a facility supported by the California Institute for Regenerative Medicine.

The new $62 million institute is located on the universitys Sacramento campus, where collaborative, team-oriented science is working to advance breakthrough discoveries and bring stem cell therapies and cures to patients everywhere. It benefits from being on a campus near a nationally-designated cancer center, a renowned neurodevelopmental institute, state-of-the-art imaging and biophotonics programs, and an academic medical center that is at the forefront of advanced patient care. The UC Davis School of Veterinary Medicine and the California National Primate Research Center, both of which are in nearby Davis, also offer unique research benefits for UC Davis scientists.

The institutes facilities include primary laboratories, a shared-vector core, microscopy and cell sorters, space for academic, postdoctoral and administrative offices, along with conference rooms and a proposed lecture hall.

The institute also is home to one of the largest, most advanced, academic Good Manufacturing Practice (GMP) facilities in the nation. With approximately 7,000 square feet of space, this GMP laboratory contains a suite of six specially designed rooms that enable researchers to safely process cellular and gene therapies for clinical trials. The facility is used by both UC Davis researchers and stem cell investigators from throughout the state and beyond.

Institute Goals

The UC Davis stem cell program brings together resources from across the university to ensure that bench research the work done in laboratories can be translated successfully into clinical treatments.

With an ability to repair damaged tissue and develop into specialized cells and organs, stem cells will have a major impact in medicine and health care. Research into stem and progenitor cell therapies is in full motion throughout the university. Scientists are exploring and testing different techniques and approaches in laboratories so that new and safe therapies are available to patients. This translation of basic scientific discoveries into novel therapies and clinical practices is a hallmark of research at UC Davis

Disease Teams

See more here:
UC Davis Institute for Regenerative Cures - UC Davis Health System

New hope for stem cells, regenerative medicine emerges from the lab

5 hours ago In the right column, four images confirm the successful in vivo reprogramming of somatic liver cells (blue) into stem cells (pink), versus a control (left column). Credit: JoVE, the Journal of Visualized Experiments

Today, December 17, JoVE, the Journal of Visualized Experiments, has published a novel technique that could resolve a snag in stem cell research for application in regenerative medicinea strategy for reprograming cells in vivo to act like stem cells that forgoes the risk of causing tumors.

Dr. Kostas Kostarelos, principal investigator of the Nanomedicine Lab at the University of Manchester, said that he and his colleagues have discovered a safe approach to reprogramming somatic cells (which constitute most of the cells in the body) into induced pluripotent stem (iPS) cells. Research in this field has been embraced as an alternative to the controversial use of embryonic stem cells.

"We have induced somatic cells within the liver of adult mice to transiently behave as pluripotent stem cells," said Dr. Kostas Kostarelos, the lab's principal investigator, "This was done by transfer of four specific genes, previously described by the Nobel-prize winning Shinya Yamanaka, without the use of viruses but simply plasmid DNA [a small circular, double-stranded piece of DNA used for manipulating gene expression in a cell]."

The technique comes as an alternative to Dr. Shinya Yamanaka's reprograming methods, which won him the Nobel prize in 2012. Dr. Yamanaka's approach involved reprogramming somatic cells in vitro by introducing four genes through the use of a virus. While promising, the use of this method has been limited. As Dr. Kostarelos's article states, "One of the central dogmas of this emerging field is that in vivo implantation of [these stem] cells will lead to their uncontrolled differentiation and the formation of a tumor-like mass."

This video is not supported by your browser at this time.

Dr. Kostarelos and his team have determined that their technique does not share the risk of uncontrolled stem cell growth into tumors as seen in in vitro, viral-based methods. "[This is the] only experimental technique to report the in vivo reprogramming of adult somatic cells to pluripotency using non-viral, transient, rapid and safe methods," Kostarelos said.

The Nanomedicine Lab's approach involves injecting large volumes of plasmid DNA to reprogram cells. However, because plasmid DNA is short-lived in this scenario, the risk of uncontrolled growth is reduced.

The research group chose to publish their technique with JoVE as a means to emphasize the novelty, uniqueness and simplicity of their procedure. Along with their article, a demonstration of their technique has been published as a peer-reviewed video to ensure the proper replication of this technique by other researchers in the field.

Explore further: Test to improve stem cell safety

See more here:
New hope for stem cells, regenerative medicine emerges from the lab

Cedars-Sinai Medical Tipsheet for Dec. 2013

Contact Information

Available for logged-in reporters only

Scientists Design and Test New Approach for Corneal Stem Cell Treatments Researchers in the Cedars-Sinai Regenerative Medicine Institute have designed and tested a novel, minute-long procedure to prepare human amniotic membrane for use as a scaffold for specialized stem cells that may be used to treat some corneal diseases. This membrane serves as a foundation that supports the growth of stem cells in order to graft them onto the cornea. This new method, explained in a paper published in the journal PLOS ONE, may accelerate research and clinical applications for stem cell corneal transplantation. CONTACT: Cara Martinez, 310-423-7798; Email cara.martinez@cshs.org; Twitter @CedarsSinaiCara

Cancer Science Evolves, One Consent Form at a Time Tucked away in freezers chilled to minus 80 degrees Celsius are blood and tissue samples from Cedars-Sinai patients. The freezers that hold these samples also contain the hopes of investigators determined to uncover new treatments for cancer patients across the globe. As cancer research continues to evolve, scientists rely on specimen samples, such as tissue, blood or urine, from generous patients to advance discoveries and personalize care. Biobanks, like the state-of-the-art biobank at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, allow patients to make invaluable contributions to medical research and treatment advances that may ultimately be the solution to their own diagnosis or disease down the road. CONTACT: Cara Martinez, 310-423-7798; Email cara.martinez@cshs.org; Twitter @CedarsSinaiCara

Cedars-Sinai, UCLA Health System and Select Medical Announce Partnership to Open Medical Rehabilitation Hospital Cedars-Sinai, UCLA Health System and Select Medical announced today a partnership to create a 138-bed acute inpatient rehabilitation hospital located in the former Century City Hospital. With an expected opening in late 2015, the rehabilitation hospital will serve the growing needs in the community for inpatient rehabilitation, and is also expected to serve as a center for treating complex rehabilitation cases from throughout the nation. The joint venture is an LLC partnership among Cedars-Sinai, UCLA Health System and Select Medical. The vision of the partnership is to develop a world-class regional rehabilitation center providing highly specialized care, advanced treatment, and leading-edge technologies to treat individuals with spinal cord injuries, brain injuries, stroke, amputation, neurological disorders, and musculoskeletal and orthopedic conditions. CONTACT: Sally Stewart, 310-248-6566; Email sally.stewart@cshs.org

Cedars-Sinai Receives Fourth Straight Magnet Recognition for Nursing Excellence from American Nurses Credentialing Center For the fourth time in a row, the American Nurses Credentialing Center has granted Cedars-Sinai the Magnet recognition, the most prestigious designation a healthcare organization can receive for excellence in nursing and patient outcomes. Cedars-Sinai in 2000 became the first Southern California hospital to earn the Magnet honor; it is the only hospital in the state to be granted the designation four times. Cedars-Sinai joins a select list of only 12 hospitals worldwide that have earned Magnet recognition four times. CONTACT: Sally Stewart, 310-248-6566; Email sally.stewart@cshs.org

Ovarian Cancer Discovery Deepens Knowledge of Survival Outcomes Researchers in the Womens Cancer Program at Cedars-Sinais Samuel Oschin Comprehensive Cancer Institute have identified a series of 10 genes that may signify a trifecta of benefits for women diagnosed with ovarian cancer and ultimately reflect improved survival outcomes. The research found that the 10-gene biomarker panel may identify the aggressiveness of a patients disease, help predict survival outcomes and result in novel therapeutic strategies tailored to patients with the most adverse survival outcomes. CONTACT: Cara Martinez, 310-423-7798; Email cara.martinez@cshs.org; Twitter @CedarsSinaiCara

# # #

The rest is here:
Cedars-Sinai Medical Tipsheet for Dec. 2013